Compare Gilead Sciences, Inc. (GILD) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs State Street PDR S&P Retail ETF — how do they compare? Gilead Sciences, Inc. trades at $150.85 (market cap $182.40B), while State Street PDR S&P Retail ETF trades at $83.75 (market cap $389.66M). The key difference: Gilead Sciences, Inc. is far larger — about 468.1× State Street PDR S&P Retail ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while State Street PDR S&P Retail ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and State Street PDR S&P Retail ETF for 44 Days on average.
| GILD | XRT | |
|---|---|---|
Market Cap | $182.40B | $389.66M |
Volume | 4,469,821 | 4,275,820 |
Sector | Health | Broad Market / Factor |
52-Week High | $155.80 | $92.35 |
52-Week Low | $116.74 | $77.28 |
Typical Hold Time | 111 Days | 44 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
XRT (SPDR S&P Retail ETF) trades at $83.45, up 0.65% with a bullish technical signal despite bearish moving averages. The ETF faces mixed sentiment as retail sales show volatility, with August's 1.2% rebound contrasting July's 0.6% decline. Key resistance sits at $85, while RSI-6 at 84.45 indicates potential overbought conditions. Recent news highlights holiday sales projections exceeding $1 trillion but concerns over consumer spending shifts toward value-oriented purchases.
Outlook remains cautious amid macroeconomic pressures; higher interest rates and inflation weigh on consumer sentiment, with analysts expecting continued underperformance versus broader markets. The ETF's equal-weight approach provides diversification, but selective consumer spending patterns and oil price volatility pose near-term risks. Investment appeal hinges on holiday season performance and Federal Reserve policy direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
